Lee’s Pharma has in-licensed China Rights to tafoxiparin, a clinical-stage product from Dilafor AB of Sweden. Tafoxiparin is a heparin derivative that has completed a Phase II trial as a treatment to induce labor. Lee’s will be responsible for conducting Phase II and III trials of the drug in China. Specific financial terms of the deal were not disclosed.